Papers by Wei Hu · AgingResearch.News

Internal and Emergency Medicine2 Oct
ARNI links to lower osteoporosis risk in heart failure
Patients taking an ARNI had an adjusted hazard ratio of 0.6 for osteoporosis compared with those taking an ACE inhibitor.Patients taking an ARNI had an adjusted hazard ratio of 0.6 for osteoporosis compared with those taking an ACE inhibitor.
Cohort study of 12,808 peopleOsteoporosis
Paper
Biomolecules & Biomedicine29 Sep
Adjunctive screening and risk stratification performance of neutrophil-to-lymphocyte ratio for gestational diabetes mellitus: A systematic review and meta-analysis
Meta-analysis of observational studiesNeutrophil-to-lymphocyte ratio
Paper
Obesity Research & Clinical Practice15 Sep
A multicenter real-world study on the safety and effectiveness of the glucagon-like peptide-1 receptor agonist (liraglutide) in adolescents with obesity in Taiwan
Trial in 41 peopleGLP-1 receptor agonists
Paper
Frontiers in Nutrition13 Sep
Lifestyle mediates the association between normal-weight visceral obesity and MASLD in older adults with hypertension and diabetes
Study in peoplePopulations
Paper

Frontiers in Medicine10 Sep
Development of a CHD risk prediction model using novel lipid markers based on lipidomics and VAP technology
Case-control study of 624 peopleBiomarkers
Paper
Annals of Global Health29 Aug
Catching Up on Mortality, Falling Behind on Disability: A Dynamic Decomposition of the Health-Adjusted Life Expectancy Gap between Higher-Income and Lower-Income Countries
Computational studyPopulations
Paper
ADA Scientific Sessions 2026 Abstract6 Jun
A Novel Dual-Endpoint Model to Simultaneously Predict Risks of Type 2 Diabetes and Cardiovascular Disease in Prediabetes
Study in peopleBiomarkers
Paper
ADA Scientific Sessions 2026 Abstract5 Jun
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZT006 Tablet, an Oral GLP-1 Receptor Agonist Peptide, in Healthy Participants, Participants with Overweight or Obesity: A Phase 1 Study
Trial in peopleInterventions
Paper
ADA Scientific Sessions 2025 Abstract13 Jun
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS9531 Tablet, an Oral Dual GLP-1/GIP Receptor Agonist, in Healthy Participants—A Phase 1 Study
Trial in peopleInterventions
Paper
ADA Scientific Sessions 2025 Abstract13 Jun
HDM1002 in Chinese Adults with Overweight or Obesity—A Randomized, Placebo-Controlled, Four-Week, Phase 1b Study
Trial in peopleInterventions
Paper
ADA Scientific Sessions 2025 Abstract13 Jun
Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HDM1005)—A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose-Escalation Study
Trial in peopleInterventions
Paper